Heterogeneity of myocardial iron distribution in response to chelation therapy in patients with transfusion-dependent anemias

被引:0
|
作者
Kate Hanneman
Vikram M. Raju
Hadas Moshonov
Richard Ward
Bernd J. Wintersperger
Andrew M. Crean
Heather Ross
Elsie T. Nguyen
机构
[1] University of Toronto,Division of Cardiothoracic Imaging, Department of Medical Imaging, University Health Network, Toronto General Hospital
[2] University of Toronto,Division of Hematology, Department of Medicine, Toronto General Hospital
[3] University of Toronto,Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network
关键词
Magnetic resonance imaging; T2* imaging; Thalassemia; Iron overload; Cardiomyopathy;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this study is to examine the effect of different iron chelation regimens on the distribution of myocardial iron in patients with transfusion-dependent anemias. Institutional review board approval was obtained. Patients treated with iron chelation therapy who had undergone baseline and 1-year follow-up cardiac T2* MR studies in a four-year period were identified retrospectively. One hundred and eight patients (44 % male, mean age 31.6 ± 9.7 years) were included. The interventricular septum on three short-axis slices (basal, mid and apical) was divided into anterior and inferior regions of interest for T2* analysis. Cardiac iron concentration (CIC) was calculated from T2* values. Statistical analysis included analysis of variance and paired t-test, using Bonferroni adjustment in all pairwise comparisons. At baseline, T2* measurements varied significantly across all six regions (p < 0.001): lowest in the mid anteroseptum (mean 22.3 ± 10.1 ms) and highest in the apical inferoseptum (mean 26.2 ± 12.8 ms). At follow-up, T2* and CIC values improved significantly in all segments [mean change of 3.78 ms (95 % CI (2.93, 4.62), p < 0.001) and 0.23 mg/g (95 % CI (0.16, 0.29), p < 0.001), respectively]. Change in T2* values varied significantly between segments (p < 0.001) with greatest improvement in the apical inferoseptum [4.26 ms, 95 % CI (2.42, 6.11)] and least improvement in the basal anteroseptum [2.95 ms, 95 % CI (1.37, 4.54)]. The largest improvement in T2* values was noted in patients treated with deferiprone [4.96 ms, 95 % CI (2.34, 7.58)]. There was a statistically significant difference in improvement in CIC values between chelation regimens (p = 0.016). This is the first study to report heterogeneity in response to iron chelating drugs with variable segmental changes in T2* values.
引用
收藏
页码:1517 / 1526
页数:9
相关论文
共 50 条
  • [21] IRON CHELATION IN TRANSFUSION-DEPENDENT THALASSEMIA WITH CHRONIC HEPATITIS
    DEVIRGILIIS, S
    COSSU, P
    SANNA, G
    FRAU, F
    LOI, E
    LOBRANO, R
    NUCARO, A
    TOCCAFONDI, C
    CORNACCHIA, G
    LOI, A
    CAO, A
    ACTA HAEMATOLOGICA, 1982, 67 (01) : 49 - 56
  • [22] Early cardiac iron overload in children with transfusion-dependent anemias
    Fernandes, Juliano Lara
    Fabron, Antonio, Jr.
    Verissimo, Monica
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (12): : 1776 - 1777
  • [23] COMBINED CHELATION THERAPY WITH DEFERASIROX AND DEFEROXAMINE IN TRANSFUSION-DEPENDENT PATIENTS WITH THALASSEMIA
    Ladis, V.
    Delaporta, P.
    Kyriakopoulou, D.
    Kattamis, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 703 - 703
  • [24] MEDICAL COMPLICATIONS AND RESOURCE UTILIZATION IN BLOOD TRANSFUSION-DEPENDENT PATIENTS WITH MYELOFIBROSIS BY IRON CHELATION THERAPY USE
    Vekeman, F.
    Huynh, L.
    Sasane, M.
    Cheng, W.
    Duh, M. S.
    Paley, C.
    Mesa, R.
    VALUE IN HEALTH, 2014, 17 (03) : A225 - A225
  • [25] Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
    Forni, Gian Luca
    Kattamis, Antonis
    Kuo, Kevin H. M.
    Maggio, Aurelio
    Sheth, Sujit
    Taher, Ali T.
    Viprakasit, Vip
    PEDIATRIC BLOOD & CANCER, 2024, 71 (08)
  • [26] Development of an adherence to Iron-Chelation Therapy measure through a qualitative study: patient and caregiver perspectives in transfusion-dependent anemias and myelodysplastic syndrome
    Lasch, Kathryn E.
    Horodniceanu, Erica G.
    Bal, Vasudha
    Cote, Isabelle
    Dorgan, Amy
    Malet, Isabelle
    QUALITY OF LIFE RESEARCH, 2014, 23 : 105 - 105
  • [27] The Non-adherence to iron chelation therapy ( ICT) among transfusion-dependent thalassemia ( TDT) patients in Pakistan
    Arif, Fariha
    Qazi, Zunaira
    Maqsood, Amna
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2023, 73 (09) : 1939 - 1939
  • [28] IRON CHELATION THERAPY IN TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE STUDY OF 53 PATIENTS IN A SINGLE INSTITUTION
    Finelli, C.
    Clissa, C.
    Barraco, M.
    De Maio, C.
    Fogli, M.
    Stanzani, M.
    Parisi, S.
    Paolini, S.
    Bosi, C.
    Cavo, M.
    HAEMATOLOGICA, 2017, 102 : 57 - 57
  • [29] Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients
    Bordbar, Mohammadreza
    Haghpanah, Sezaneh
    Zekavat, Omid Reza
    Saki, Forough
    Bazrafshan, Asghar
    Bozorgi, Haleh
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (11) : 997 - 1003
  • [30] Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia
    Lal, Ashutosh
    Sweeters, Nancy
    Ng, Vivian
    Foote, Drucilla
    Evans, Patricia
    Neumayr, Lynne
    Kurio, Gregory
    Harmatz, Paul
    Porter, John B.
    Vichinsky, Elliott
    BLOOD, 2010, 116 (21) : 1732 - 1733